What is Eupraxia Pharmaceuticals Inc. (EPRXF)?

Eupraxia Pharmaceuticals Inc. (EPRXF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of EPRXF?

The current price of EPRXF is $3.04. Prices are updated in real time on Stocks360.

What is EPRXF's price-to-earnings (PE) ratio?

EPRXF's trailing twelve-month PE ratio is -2.68, based on current price and earnings per share data available on Stocks360.

What is EPRXF's market capitalization?

EPRXF's market capitalization is $108,291,792.00, placing it in the small-cap tier.

Eupraxia Pharmaceuticals Inc. (EPRXF)

Stock analysis · OTC · Healthcare · Biotechnology

$3.04

Market Cap

$108.29M

PE (TTM)

-2.68

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.40

Day Range

$3.04 – $3.24

52-wk Range

$2.93 – $6.78

Avg Volume

N/A

Volume

800.00

Eupraxia Pharmaceuticals Inc. (EPRXF) is a publicly traded company in the Healthcare sector. Latest price: $3.04. Market cap $108.29M. Trailing PE -2.68. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

Earnings

Most Recent

Apr 1, 2024

EPS $-0.21 vs est. $-0.18

Missed by $0.03

Proprietary Signals

Signal snapshot temporarily unavailable.

About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc. operates as a clinical-stage biotechnology firm, focusing its efforts on the discovery, advancement, and commercialization of innovative technologies within the biotech landscape. The company's leading therapeutic compound, EP-104IAR, is currently progressing through Phase II clinical trials. This candidate is designed to address pressing unmet medical needs and provide pain relief for individuals suffering from knee osteoarthritis. Additionally, its potential is being explored for the treatment of osteoarthritis in animal companions, specifically dogs and horses. Eupraxia's development pipeline also features other significant programs, including EP-201, an antibiotic intended to prevent or treat infections following surgical procedures, and EP-105, an extended-release anesthetic aimed at managing post-surgical pain effectively. Furthermore, the company is actively pursuing the development of novel drug candidates for various oncological indications. Founded in 2011, the company was initially known as Plaza Capital Partners Inc. before officially adopting the name Eupraxia Pharmaceuticals Inc. in May 2012. Its principal operations are based in Victori…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.68×
P/S (TTM)	0.00×
P/B	35.05×
P/FCF (TTM)	-5.39×
EV / EBITDA	-3.73×
EV / Sales	0.00×
Earnings Yield	-37.19%
Free Cash Flow Yield	-18.54%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$139.38M
Net Income (TTM)	-$56.19M
Free Cash Flow (TTM)	-$26.44M
Net Debt	-$11.72M
Working Capital	$565.91K
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-482.83%
Return on Invested Capital	-252.70%